SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at two investor conferences in November:
|Lazard Capital Markets 9th Annual Healthcare Conference in New York|
|Wednesday, November 14 at 2:30 p.m. ET.|
|Piper Jaffray 24th Annual Healthcare Conference in New York|
|Tuesday, November 27 at 12:30 p.m. ET.|
Donald J. Santel, Chief Executive Officer of Hyperion, will provide a company overview. To access the live webcasts and subsequent archived recordings, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
About Hyperion Therapeutics
Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.
CONTACT: Shari Annes, Investor Relations Cell: 650-888-0902 email@example.comSource:Hyperion Therapeutics, Inc.